Myelodysplastic syndrome with karyotype abnormality is associated with elevated F‐cell production

Craig, Jamie E; Sampietro, Maurizio; Oscier, David; Contreras, M.; Thein, S L

doi:10.1046/j.1365-2141.1996.d01-1682.x

Cited by 20 publications

(13 citation statements)

References 15 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The sample size of the present study was not high enough to allow for statistical comparisons of patients with different FAB subtypes. The association of increased hemoglobin F with karyotype abnormalities, as described by Craig et al [7], was not observed in our patients.…”

Section: Discussionmentioning

confidence: 47%

Hemoglobin F in myelodysplastic syndrome

Reinhardt

Haase

Schoch

et al. 1998

Annals of Hematology

View full text Add to dashboard Cite

Reactivation of fetal hemoglobin synthesis in adulthood can be seen in hematological disorders affecting the erythropoietic system. The objective of the present study was to evaluate the incidence and prognostic significance of increased hemoglobin F in patients with myelodysplastic syndrome. Hemoglobin F concentrations and Ggamma/Ggamma + A gamma-globin chain ratios were determined in 26 patients with primary myelodysplastic syndrome. Median age of the patients was 65 years; all FAB subtypes were included. Increased hemoglobin F concentration of up to 20% of total hemoglobin (normal: below 2%) was seen in 16 patients; ten patients had normal values. There was a significant relation between hemoglobin F concentration and the course of disease, e.g., 12 of the 16 patients with elevated hemoglobin F survived at least 1 year after the examination, in contrast to only three of the ten patients with normal hemoglobin F (p < 0.025). All of six patients with hemoglobin F above 5% survived at least 1 year. There was no significant difference in the hemoglobin F concentration between patients with and without cytogenetic anomalies. The Ggamma/Ggamma + A gamma-globin chain ratio was slightly elevated in all patients, with a weak correlation to the degree of hemoglobin F elevation. The values were not of additional prognostic significance. The data of the present study suggest that the hemoglobin F concentration may be a prognostic parameter in myelodysplastic syndrome; increased hemoglobin F concentration may indicate a better prognosis.

show abstract

Section: Discussionmentioning

confidence: 47%

Hemoglobin F in myelodysplastic syndrome

Reinhardt

Haase

Schoch

et al. 1998

Annals of Hematology

View full text Add to dashboard Cite

show abstract

“…14 Reactivation of HbF production in patients with MDS is a common phenomenon and an elevated F cell count has been reported to be a possible prognostic factor for MDS. 7,17,21 The present study is the first documentation that F blasts are found frequently in most patients with MDS. We investigated the F blast levels in MDS patients and non-MDS patients with stress erythropoiesis.…”

Section: Discussionmentioning

confidence: 92%

“…Similar data on HbF expression in erythrocytes were reported previously by other investigators, who found elevated HbF concentrations in up to 50% of MDS patients tested. 9,19,20 Craig et al 21 found that the mean F cell percentage in MDS patients was not statistically different from that in normal blood donors. In contrast, in the present study, HbF-containing erythrocytes in the bone marrow were seven times as abundant in patients with MDS as in healthy controls.…”

Section: Discussionmentioning

confidence: 99%

Significance of fetal hemoglobin-containing erythroblasts (F blasts) and the F blast/F cell ratio in myelodysplastic syndromes

et al. 2002

View full text Add to dashboard Cite

To investigate the relationship between the fetal hemoglobincontaining erythroblasts (F blasts) and apoptosis in myelodysplastic syndromes (MDS), we immunohistochemically assessed F blasts, F cells, and apoptosis in 137 patients with MDS. A marked increase in the number of F blasts in the bone marrow was identified in 116 of 137 patients (84.7%), and the number of F cells was elevated in 54 patients (39.4%). Among the erythroblasts stained by anti-glycophorin C antibody, the mean percentage of F blasts was 14.63 ؎ 9.17% in MDS, which was significantly higher than that in non-MDS patients with stress erythropoiesis (4.82 ؎ 3.35%, P Ͻ 0.01), although there were no significant differences in the number of F cells between these groups. In particular, 62 of the 137 MDS patients (45.3%) had an apparent increase in F blasts but no elevation of F cells. The apoptotic rate was significantly higher in the patients with a F blast/F cell (Fb/Fc) ratio у5.0 than in those with a Fb/Fc ratio Ͻ1.0 (P Ͻ 0.01). The results indicate that F cell precursors are incapable of maturing into functioning endstage F cells, presumably owing to apoptotic cell death. The measurement of F blasts in the bone marrow is needed for the precise evaluation of fetal-type erythropoiesis in MDS.

show abstract

“…The increase in F-cell or HbF levels parallels an improved clinical course in both sickle cell disease and thalassemia (Breymann et al, 1999;Nagel et al, 1993); however, since the therapies that induce increased F cells and HbF all have toxic side effects, it follows that therapeutic monitoring by F-cell enumeration should facilitate more optimal dosing for these patients. Additionally, studies have indicated that F-cell or HbF levels may be of prognostic value for evaluation of patients with myelodysplasia or thalassemia (Craig, Sampietro, Oscier, Contreras, & Thein, 1996;Liu, Seong, & Lin, 1997;Luna-Fineman et al, 1999;Reinhardt et al, 1998). Additionally, studies have indicated that F-cell or HbF levels may be of prognostic value for evaluation of patients with myelodysplasia or thalassemia (Craig, Sampietro, Oscier, Contreras, & Thein, 1996;Liu, Seong, & Lin, 1997;Luna-Fineman et al, 1999;Reinhardt et al, 1998).…”

Section: Of 17mentioning

confidence: 99%

Enumeration of Fetal Red Blood Cells, Hemoglobin‐Specific RBC Cells, and F Reticulocytes in Human Blood

Davis

2019

CP Cytometry

View full text Add to dashboard Cite

Recent advances in analytical cytometry have improved diagnostic tools for the study of erythropoiesis in anemic patients and resolution of differential diagnosis in diseases of the erythron. This article presents three applications of red blood cell (RBC) analysis-quantitation of fetal red cells, F-cell enumeration, and F-reticulocyte analysis-which improve diagnostic precision, sensitivity, and specificity, and provide better laboratory indicators of therapeutic efficacy in a variety of hematologic and obstetric disorders. Such advances also include the measurement and quantitation of RBC hemoglobins and their relative ribonucleic acid levels. These advances not only promise to improve diagnostic accuracy and laboratory precision over techniques such as the traditional manual reticulocyte counting method and the Kleihauer-Betke stain method for evaluating fetomaternal hemorrhage (FMH), but also serve as tools for newer assays of anemia diagnosis and improved clinical outcomes. In addition to the primary methods, supporting techniques for preparing spiked controls, automating data analysis, setting up a fetal hemoglobin acquisition protocol, and assaying reticulocytes using thiazole orange are also presented. C 2019 by John Wiley & Sons, Inc. Keywords: F cells r F reticulocytes r fetal hemoglobin r fetal red cells r fetomaternal hemorrhage r flow cytometry r hemoglobin levels r red blood cells How to cite this article: Davis, B. H. (2019). Enumeration of fetal red blood cells, hemoglobin-specific RBC cells, and F reticulocytes in human blood.

show abstract

Myelodysplastic syndrome with karyotype abnormality is associated with elevated F‐cell production

Cited by 20 publications

References 15 publications

Hemoglobin F in myelodysplastic syndrome

Hemoglobin F in myelodysplastic syndrome

Significance of fetal hemoglobin-containing erythroblasts (F blasts) and the F blast/F cell ratio in myelodysplastic syndromes

Enumeration of Fetal Red Blood Cells, Hemoglobin‐Specific RBC Cells, and F Reticulocytes in Human Blood

Contact Info

Product

Resources

About